[CDXC] 주사제 승인

ChromaDex Corp. Launches Niagen+, the First Pharmaceutical-Grade Intravenous and Injectable Niagen®

 

ChromaDex Corp. (NASDAQ

) has introduced Niagen+, a first-of-its-kind pharmaceutical-grade Niagen® (nicotinamide riboside chloride or NRC). Approved by the U.S. FDA for compounding by 503B outsourcing facilities, Niagen+ will be available in intravenous (IV), shot, and push forms exclusively at clinics, with a prescription. ChromaDex aims to be the first company in the U.S. to offer Niagen as both a direct-to-consumer dietary supplement (Tru Niagen®) and a pharmaceutical-grade product for clinical use. The company holds various patents, including a pending patent for NRC and other NAD+ precursors for IV use, providing extensive protection.